Pfizer's vaccine for Clostridium difficile (C. US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by ...
Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback